Therapeutic Advances in Gastroenterology, 2018 Background: As the patents of originator biologics are expiring, biosimilar versions are becoming available for the treatment of inflammatory bowel disease (IBD).
Viktoria Bergqvist +11 more
doaj +2 more sources
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseases [PDF]
Therapeutic Advances in Gastroenterology, 2016 Infliximab was the first monoclonal antibody used in the treatment of inflammatory bowel disease (IBD). Over several years, this antitumour necrosis factor (TNF) treatment proved its efficacy in both induction and maintenance therapy.
Joanna Sieczkowska +4 more
doaj +3 more sources
Retention Rate and Safety of Biosimilar CT-P13 in Rheumatoid Arthritis: Data from the Korean College of Rheumatology Biologics Registry. [PDF]
BioDrugs, 2020 OBJECTIVE: The aim was to evaluate long-term drug retention, discontinuation, efficacy and safety of CT-P13 and reference infliximab in patients with rheumatoid arthritis (RA) enrolled in the Korean College of Rheumatology Biologics (KOBIO) registry ...
Kim HA +6 more
europepmc +4 more sources
Switching From Reference Infliximab to Biosimilar CT-P13 Did Not Change Quality of Life in Stable Inflammatory Bowel Disease Patients. [PDF]
Crohns Colitis 360, 2022 Lay Summary Patients with inflammatory bowel disease were switched from the originator infliximab to the biosimilar CT-P13. Before and after switching they filled in questionnaires.
Pierik MJ +11 more
europepmc +4 more sources
مجلة كلية الطب, 2023 Background: Ankylosing spondylitis is a rare disease affecting people with hereditary factors. Its treatment includes life style modification and use of drugs such as the biologic agent infliximab or its biosimilar, CT-P13 infliximab.
Mohammed M. Kamil +2 more
doaj +1 more source
Real-world data on the infliximab biosimilar CT-P13 (Remsima®) in inflammatory bowel disease. [PDF]
World J Clin Cases, 2021 In recent years, biological therapies have revolutionized the management of inflammatory bowel disease (IBD); however, they are expensive. The development of biosimilar products has allowed us to reduce healthcare costs and improve patients' access to these treatments.
Huguet JM +7 more
europepmc +5 more sources
Frontiers in Pharmacology, 2022 Background: Many pediatric inflammatory bowel disease (IBD) patients are now using biosimilars of anti-tumor necrosis factor-α (TNF-α), with increasing trends in recent years.
Valeria Dipasquale +3 more
doaj +1 more source
Current status of biosimilars in the treatment of inflammatory bowel diseases [PDF]
Intestinal Research, 2016 Introduction of biological therapies have led to dramatic changes in the management of debilitating immune-mediated inflammatory bowel diseases (IBD) including ulcerative colitis and Crohn's disease. However, the long term use of these agents may be very
Dong Il Park
doaj +1 more source
Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial [PDF]
, 2020 Objective. To assess non-inferiority of s.c. to i.v. CT-P13 in RA. Methods. Patients with active RA and inadequate response to MTX participated in this phase I/III double-blind study at 76 sites. Patients received CT-P13 i.v. 3 mg/kg [week (W) 0 and W2]
Shevchuk, Sergii +22 more
core +1 more source
Letter: treatment with subcutaneous CT‐P13 in Crohn’s disease patients with intravenous infliximab failure [PDF]
Alimentary Pharmacology & Therapeutics, 2022 LINKED CONTENTThis article is linked to Hanzel et al papers.
Caron, Bénédicte +3 more
openaire +3 more sources